Ethyl 5-piperazin-1-ylpyridine-3-carboxylate | 1248731-24-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: Ethyl 5-piperazin-1-ylpyridine-3-carboxylate
• CAS: 1248731-24-9
• 化学式: C₁₂H₁₇N₃O₂
• 分子量: 235.286
• InChiKey: JMFJENISZMTAGC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  17
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  54.5
• 氢给体数：
  1
• 氢受体数：
  5

文献信息

• GLYCINE COMPOUND
  申请人：Yoshihara Kousei

  公开号：US20120184520A1

  公开（公告）日：2012-07-19

  [Problem] The present invention provides a compound which is useful as an active ingredient of a pharmaceutical composition, in particular, a pharmaceutical composition for preventing and/or treating VAP-1-related diseases. [Means for Solution] The present inventors have conducted intensive studies on a compound having a VAP-1 inhibitory activity, and as a result, they have found that a compound of the present invention or a salt thereof exhibits an excellent VAP-1 inhibitory activity and is useful for preventing and/or treating VAP-1-related diseases, in particular, diabetic nephropathy or diabetic macular edema, thereby completing the present invention. The present invention further relates to a pharmaceutical composition, in particular, a pharmaceutical composition for preventing and/or treating VAP-1-related diseases, which comprises the compound of the present invention or a salt thereof, and an excipient.

  本发明提供了一种化合物，该化合物可用作药物组合物的活性成分，特别是用于预防和/或治疗与VAP-1相关的疾病的药物组合物。 本发明的解决方案是，本发明者对具有VAP-1抑制活性的化合物进行了深入研究，结果发现本发明的化合物或其盐表现出优异的VAP-1抑制活性，并且对于预防和/或治疗与VAP-1相关的疾病，特别是糖尿病肾病或糖尿病黄斑水肿，具有用处，从而完成了本发明。本发明还涉及一种药物组合物，特别是用于预防和/或治疗与VAP-1相关的疾病的药物组合物，其包括本发明的化合物或其盐以及赋形剂。
• Piperidine and piperazine derivatives as autotaxin inhibitors
  申请人：Merck Patent GmbH

  公开号：EP2623491A2

  公开（公告）日：2013-08-07

  The present invention relates to piperidine and piperazine derivatives according to formulae (Ia), (Ib) and (II) as autotaxin inhibitors and the use of such compounds for the treatment and/or prophylaxis of physiological and/or pathophysiological conditions, which are caused, mediated and/or propagated by increased lysophosphatic acid levels and/or the activation of autotaxin, in particular of different cancers.

  本发明涉及根据式（Ia）、（Ib）和（II）作为自旋素抑制剂的哌啶和哌嗪衍生物，以及将此类化合物用于治疗和/或预防生理和/或病理生理状况，这些状况是由溶血磷脂酸水平升高和/或自旋素活化引起、介导和/或传播的，尤其是不同的癌症。
• PIPERIDINE AND PIPERAZINE DERIVATIVES AS AUTOTAXIN INHIBITORS
  申请人：Schiemann Kai

  公开号：US20120059016A1

  公开（公告）日：2012-03-08

  The present invention relates to piperidine and pyrazine derivatives according to formulae (Ia), (Ib) and (II) as autotaxin inhibitors and the use of such compounds for the treatment and/or prophylaxis of physiological and/or pathophysiological conditions, which are caused, mediated and/or propagated by increased lysophosphatic acid levels and/or the activation of autotaxin, in particular of different cancers.
• US20140343075A1
  申请人：——

  公开号：US20140343075A1

  公开（公告）日：2014-11-20
• US8802679B2
  申请人：——

  公开号：US8802679B2

  公开（公告）日：2014-08-12